Respire_final-01
  • CORPORATE
    • Company Overview
    • Board of Directors
    • RespireRx Organization Structure
    • Social Media Guidelines
  • NEUROTRANSMISSION
  • RESOLUTIONRX
    • Cannabinoid Platform Summary
    • Pharmaceutical Cannabinoids
    • Obstructive Sleep Apnea
    • Dronabinol for the Treatment of Obstructive Sleep Apnea
    • Regulatory Process
  • ENDEAVOURRX
    • Neuromodulators
    • Ampakines
      • AMPAkine Platform Summary
      • Lead Compounds
      • Attention Deficit Hyperactivity Disorder (ADHD)
      • Spinal Cord Injury (SCI)
    • GABAkines
      • GABAkines Platform Summary
      • Background
      • Epilepsy
      • Pain
  • PRODUCT PIPELINE
  • INVESTORS
    • Investor Contact
    • SEC Reports
    • News
    • FAQs
    • Presentations
  • CONTACT

RespireRx Pharmaceuticals Inc. is a biopharmaceutical company developing innovative and revolutionary treatments to combat disorders caused by disruption of neuronal signaling.

In the News

5/29/24 – RespireRx Pharmaceuticals Inc. Announces a Department of Defense Award to Fund a Phase 2 Clinical Study to Determine the Safety and Efficacy of CX1739, its Lead AMPAkine, to Improve Bladder Function in Patients with Spinal Cord Injury

May 29, 2024j3ff1

RespireRx Pharmaceuticals Inc. Reports Publication of Preclinical Research Results Demonstrating the Ability of CX1739, its Lead Clinical AMPAkine, to Improve Bladder Function After Spinal Cord Injury

March 26, 2024j3ff1

2/13/24 – RespireRx Pharmaceuticals Inc. Reports Preclinical Pain Relief for their Non-Opioid Lead GABAkine

February 13, 2024j3ff1
All News

NEWS: RespireRx Announces Department of Defense Award to Fund Phase 2 Clinical Study for its Lead AMPAkine

Read

NEWS: RespireRx Reports Preclinical Pain Relief for their Non-Opioid Lead GABAkine

Read

©2016 RespireRx Phamaceuticals Inc. All Rights Reserved.